bioAffinity Technologies, Inc.
Nasdaq · CIK 0001712762 · Fiscal year end 1231
Latest reported period: Latest published period
Revenue
$1.4M
Operating Income
$-3.6M
Net Income
$-3.6M
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $1.4M | - | - |
| Operating Income | $-3.6M | - | - |
| Net Income | $-3.6M | - | - |
| Eps Basic | -0.81 | - | - |
| Eps Diluted | -0.81 | - | - |
| Cash And Equivalents | $3.1M | - | - |
| Total Assets | $7.9M | - | - |
| Total Liabilities | $4.3M | - | - |
| Shareholders Equity | $3.7M | - | - |
| Operating Cash Flow | $-3.2M | - | - |
| Capital Expenditures | $5,663 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | bioAffinity Technologies, Inc. | 2026-05-11 | 0001493152-26-022044 |
| 10-K | bioAffinity Technologies, Inc. | 2026-03-16 | 0001493152-26-010143 |
| 10-Q | bioAffinity Technologies, Inc. | 2025-11-14 | 0001493152-25-023405 |
| 10-Q | bioAffinity Technologies, Inc. | 2025-08-14 | 0001641172-25-024163 |